SeraNovo and Ildong Pharmaceutical to Collaborate on Research Projects
LEIDEN, the Netherlands, September 26, 2022 / B3C newswire / -- SeraNovo BV (Leiden, The Netherlands) is pleased to announce the closing of a multi compound deal with Ildong Pharmaceutical (Seoul, South Korea), a pharmaceutical company engaged in the research and development of small molecules in the field of neuroscience and oncology.
Niall Hodgins, Chief Executive Officer of SeraNovo commented: “SeraNovo has grown substantially in recent years in terms of our technical capabilities and worldwide customer base. It is great to be able to share news of one of our most important collaborations with such a historic company. Our technology will again be used to drive important therapies to patients. We look forward to a long and prosperous relationship with Ildong.”
SeraNovo is a formulation technology provider enhancing the bioavailability of poorly soluble APIs. Our team is specialized in addressing two core issues with our proprietary technology: enhancing bioavailability and reducing development time to the clinic. SeraNovo is a technology inventor and owns associated know-how and intellectual property.
About Ildong Pharmaceuticals
ILDONG Company Profile: As a leading pharmaceutical company in South Korea, ILDONG Pharmaceutical Co., Ltd. has been dedicated and committed to the development and supply of superior pharmaceutical products that contribute to the health and well-being of people. ILDONG is steadfast in our vision of continuously growing with customers as a leading global company by providing solutions for disease prevention and developing new solutions for healthier and happier lives.
This press release contains forward-looking statements, including but not limited to statements regarding development plans, formulation platforms, and product candidates and related capabilities. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from current expectations and projections. The parties expressly disclaim any intent or obligation to update these forward-looking statements except as required by law.
Niall Hodgins – CEO
Keywords: Drug Development; Solubility; Biological Availability; Solvents; Drug Delivery Systems; Biological Products; Pharmaceutical Preparations; Chemistry, Pharmaceutical; Administration, Oral; Solvents; Excipients; Industry; Netherlands; Seoul
Published by B3C newswire